
GD GUNDERSON DETTMER



Kirt W Shuldberg

PARTNER

San Diego

P +1 858 436 8060

San Francisco

P +1 415 978 9803

Kirt is a partner in our San Diego and San Francisco offices.

Kirt specializes in advising life sciences and technology companies through all stages of their growth, including pre-incorporation planning, seed and venture capital financings, mergers and acquisitions, spin outs, IPOs and other public offerings, strategic collaborations and licensing transactions, and restructurings. He regularly serves as outside general counsel to public companies. Kirt enjoys partnering with management teams and Boards to help set strategic direction and structure and negotiate complex financing and other corporate transactions. Kirt also routinely represents venture capital firms in their investment activities, related business matters and counseling. His clients include high-growth private and public life sciences and technology companies, as well as leading venture capital firms.

Kirt earned his J.D. from the University of California, Berkeley, where he was Associate Editor of the *California Law Review*, and his B.S., *magna cum laude*, from

Brigham Young University. Before joining Gunderson Dettmer, Kirt was a partner at Sheppard Mullin.

Kirt regularly speaks on topics of interest to emerging company executives and venture capital investors.

Credentials

EDUCATION

- University of California, Berkeley, School of Law, J.D.
- Brigham Young University, B.S. magna cum laude

BAR ADMISSIONS

California

Focus Areas

Corporate Governance & Strategy
Fund Investments in Companies
Initial Public Offerings (IPOs) & Direct Listings
Life Sciences
Mergers & Acquisitions
Public Companies/Public Offerings
Seed, Venture and Growth Financings

Related News & Insights

CLIENT NEWS

AIRNA Announces \$155M Series B Co-led by Venrock Healthcare and Forbion Growth

CLIENT NEWS

City Therapeutics Announces Launch with \$135M Series A Financing

CLIENT NEWS

Al Biotech Xaira Therapeutics Emerges from Stealth With \$1B in Funding

CLIENT NEWS

ARCH Venture Partners Leads \$270M Series A of Orbital Therapeutics

CLIENT NEWS

Viridos Announces its \$25M Series A Financing

CLIENT NEWS

ARCH Venture Partners Invests in Rapport Therapeutics \$100M Series A

CLIENT NEWS

Brightseed Raises \$68M Series B Financing

CLIENT NEWS

Gunderson Dettmer Clients Invest in \$215M Series B Financing of Arbor Biotechnologies

CLIENT NEWS

Xencor Collaboration Agreement with Johnson & Johnson

CLIENT NEWS

Amgen Acquisition of Rodeo Therapeutics

CLIENT NEWS

Gunderson Dettmer Advises Athlon Acquisition Corp. on Initial Public Offering

CLIENT NEWS

Gunderson Dettmer Advises Tarsus Pharmaceuticals, Inc. on Initial Public Offering

CLIENT NEWS

Amgen partners with LifeMax Laboratories in the formation of AmMaxBio, Inc.